CSL Biotherapies

8 PBAC submissions on file, active 2007–2012. 38% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Tamsulosin hydrochloride
  Urology · Recommended with restriction · 2010—
• Tapentadol
  Pain · Recommended with restriction · 2013other sponsor
• Zoster virus vaccine live (oka/merk)
  Vaccines · Recommended with restriction · 2008—
• Calcipotriol with betamethasone dipropionate, ointment
  Dermatology · Recommended with restriction · 2009—

Therapy area mix

Activity by year

2007 (1) · 2008 (3) · 2009 (1) · 2010 (1) · 2011 (1) · 2012 (1)

Rejection patterns

Across 5 Not recommended decisions on file.

• 2×uncertain clinical benefit
• 1×unacceptably high and uncertain cost-effectiveness ratios
• 1×small and clinically uncertain incremental benefit of ~2 IPSS points over placebo
• 1×strong placebo response
• 1×uncertain quality-of-life gains